摘要
目的：观察强化血糖控制对慢性阻塞性肺疾病急性加重期合并高血糖肺功能的影响,为慢性阻塞性肺疾病急性加重期合并高血糖的治疗提供理论依据和实践指导。方法：采用同期、平行、随机对照试验的方法对研究对象的肺功能进行分析。结果：治疗后两组的肺功能均有明显改善,第14d后实验组FEV1/FVC及FEV1实测/预计值较对照组比较有统计学差异,P〈0.05。结论：强化血糖控制利于患者肺功能恢复,改善患者生活质量。摘要目的：探讨瑞舒伐他汀联合依折麦布与单用瑞舒伐他汀两种调脂方案用于脑梗死患者卒中二级预防的临床效果。方法：选择2014年7月～2015年8月间收治的伴有颈动脉粥样硬化和高脂血症的脑梗死患者140例，随机分为治疗组和对照组各70例，两组患者给予抗血小板、降压等药物治疗，治疗组给予瑞舒伐他汀联合依折麦布调脂治疗，对照组给予瑞舒伐他汀调脂治疗，疗程6个月，比较两组患者血脂指标、炎性指标与颈动脉超声结果，记录随访期内临床终点事件与药物不良反应。结果：6个月后，治疗组与对照组比较LDL—C（1．82±0．72VS2．69±0．51）mmol／L、TC（3．88±0．61vs5．14±0，62）mmol／L、Apa—B（1．37±0．28vs1．79±0．38）mmol／L、hs—CRP（8．37±2．98vs11．10±3．15）mg／L显著低于对照组（P〈0．05）；治疗组患者治疗后Smax（12．27±2．71VS14．77±3．41）mm。显著低于对照组（P〈0．05），两组IMT（1．22±0．08vs1．20±0．09）mm差异无统计学差异（P〉0．05）；两组患者服药期间药物不良反应发生率（18．57％vs11．43％）及随访期内临床终点事件发生率（2．9％vs4．3％）差异均无统计学意义（P〉0．05）。结论：瑞舒伐他汀联合依折麦布调脂治疗效果优于单用瑞舒伐他汀；联合用药并未明显增加药品不良反应，可作为脑卒中患者二级预防的�
OBJECTIVE： To study the clinical efficacy of rosuvastatin combined with ezetimibe in the secondary prevention of sroke for patients with cerebral infraction. METHODS： 140 patients with cerebral infarction combined with jugular atherosclerosis and hyperlipemia from July 2014 to August 2015 were selected and randomly divided into treatment group （n = 70） and control group （n = 70）. Two groups accepted anti platelet, blood pressure eotrol and other drug treatment. The treatment group received rosuvastatin and ezetinfibe for lipid adjusting therapy, control group received rosuvastatin lonely. Blood lipid, inflammatory index and carotid artery ultrasound results in the two groups after treatment were compared. RESULTS： 6 months after treatment, in treatment group LDL -C （1.82±0.72 vs 2.69 ±0.51） mmol/L, TC （3.88 ±0.61 vs 5. 14 ±0.62） mmol/L, Apa-B （1.37 ±0.28 vs 1.79±0. 38） mmol/L and hs - CRP （8.37 ±2. 98 vs 11.10± 3. 15） mg/L were all significantly lower than those in the control group （ P 〈 0. 05）. In the treatment group after treatment Smax （12. 27 ± 2. 71 vs 14. 77 ± 3.41 ） mm2 was significantly lower than that in the control group （P 〈 O. 05）. There was no significant difference in IMT （ 1.22 ±0.08 vs 1.20 ± 0.09 ） mm （ P 〉 0.05 ）. CONCLU- SION ： Treatment efficacy of rosuvastatin combined with ezetimibe in lipid adjusting therapy is better than that in the single use of rosu- vastatin. The combined treatment does no.t significantly increase the adverse drug reactions, and can be viewed as effective in lipid ad- justing scheme for secondary prevention of stroke for patients with cerebral infraction.
作者
何军
胡仁平
柯光敏
鲍民强
吴挣
He Jun Hu Renping Ke Guangmin Bao Minqiang Wu Zheng(The Department of Neurology, The pepole＇ s Hospital of Xuan Cheng City, Xuancheng 242000, China Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, China)
出处
《国际老年医学杂志》
2016年第5期193-196,208,共5页
International Journal of Geriatrics
基金
国家自然科学基金（81070227）
关键词
瑞舒伐他汀
依折麦布
脑卒中
二级预防
调脂治疗
Rosuvastatin
Ezetimibe
Stroke
Secondary prevention
Lipid adjusting treatment
